Efficacy of Alfa EEG wave biofeedback in the management of anxiety

Pookala Bhat

Department of Psychiatry, AFMC, Pune, Maharashtra, India

Address for correspondence: Dr. Pookala Bhat, Department of Psychiatry, AFMC, Pune, Maharashtra, India. E-mail: bhatshivaram@rediffmail.com

Copyright: © Industrial Psychiatry Journal

This is an open-access article distributed under the terms of the Creative Commons Attribution-Noncommercial-Share Alike 3.0 Unported, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background:

Biofeedback is a technique in which people are trained to improve their health by learning to control certain internal bodily processes that normally occur involuntarily. Various studies in the past have shown usefulness of Alfa electroencephalographic (EEG) biofeedback in the alleviation of anxiety symptoms. Though most of the psychiatric centers in the armed forces have this facility, not much work has been done in our setup to assess its efficacy in the management of anxiety. Hence this study was undertaken.

Materials and Methods:

This study was carried out in a multispecialty Command Hospital by enrolling 100 patients with psychiatric diagnosis from both inpatient and outpatient services. The anxiety level was assessed clinically and by using Hamilton Anxiety Scale and Taylor's Manifest Anxiety Scale. One group of 50 patients was treated with Alfa EEG biofeedback sessions only, 5 times in a week for 8 weeks, along with specific pharmacotherapy. The other group was treated with appropriate dose of anxiolytics. The anxiety level was reassessed after 4 weeks and 8 weeks.

Results:

The response was better for mixed anxiety and depressive disorder with pharmacotherapy than with the biofeedback, but female patients showed better response with EEG biofeedback.

Conclusion:

In the short term, Alfa EEG biofeedback therapy is almost as efficacious as pharmacological intervention in the management of anxiety symptoms, and relatively more useful in females.

Keywords: Alfa EEG biofeedback, anxiety, pharmacotherapy

In the late 1960s, research showed that certain involuntary activities like brain activity, blood pressure, heart rate can be altered by tuning into our body. This was termed as biofeedback. Simply put, biofeedback is the technique of looking into the signals from our body, for example, measuring one's weight or temperature is a simple method of biofeedback, as both parameters feed back information about the body. Biofeedback is designed to facilitate self-regulation of bodily processes that are not easily observed (e.g., blood pressure, small muscle contraction, respiratory rate), using electronic instruments for feedback in the form of an auditory and/ or visual signal.[1]

Hammond reviewed the literature on the use of neurofeedback in cases of anxiety disorders, including posttraumatic stress disorder, obsessive compulsive disorder and depression.[2] He noted that
pharmacologic treatment may not be as effective as previously believed. EEG biofeedback was associated with minimal side effects and was less invasive than other methods for addressing biologic brain disorders. Moore reviewed the literature on the EEG biofeedback treatment of anxiety disorders.[3] He noted that alfa, theta, alfa-theta enhancements are effective and alfa suppression is less effective.

In the seventies, several studies had suggested the use of EEG modulation in stress-induced disorders. It was also found that the combination of temperature biofeedback and EEG neurofeedback helped alcoholics feel less depressed and be more likely to abstain from drinking alcohol. Thermal biofeedback helps to alleviate migraine and chronic tension headaches among children and adolescents as well. In addition to the above, biofeedback instruments can be used to measure the level of anxiety in neurotic illnesses.[4]

Recently Saldanha et al. studied the efficacy of EEG, electro myography, electro-dermal and thermal biofeedback in stress-related disorders and compared it with that of pharmacological intervention.[5] They found that a judicious combination of biofeedback with pharamcotherapy works better, and also that a period of 12 weeks of training and exercise on biofeedback is adequate for any patient.

Most of the psychiatric centers of the armed forces have biofeedback equipments, and some are having the latest computerized systems procured under the modernization plan. However, their use has been limited due to inadequate in-service data of their efficacy. Hence there is a need for systematic evaluation of efficacy of biofeedback in the management of anxiety. This study has been undertaken in this direction with a view to facilitate optimal utilization of available modern equipments.

MATERIALS AND METHODS

This study was carried out in a multispecialty Command Hospital. One hundred patients with definite psychiatric diagnosis, including those from both inpatient and outpatient services, were taken up for the study. The diagnosis was established clinically as per international classification of diseases (ICD-10) criteria.[6] Patients with past history of head injury, seizure disorders, hypertension, or diabetes mellitus were excluded from the study. Also psychotic, uncooperative and unwilling patients were not recruited for the study.

Written informed consent was obtained from all patients. A pro forma data sheet specifically designed to gather psychosocial data was used. Patients were divided into two groups by allocating consecutive patients alternately. The anxiety level was assessed initially (phase 1) using Hamilton Anxiety Scale (HAS)[7] and Taylor’s Manifest Anxiety Scale (TMAS).[8] One group of 50 patients (study group) was treated with Alfa EEG biofeedback sessions, 5 times in a week for 8 weeks, and no benzodiazepines for anxiety were administered to them. The other group (control group) was treated with appropriate dose of anxiolytics. The anxiety level was reassessed after 4 weeks (phase 2) and 8 weeks (phase 3). The data collected were analyzed using the statistical analysis software Pepi.

RESULTS

All the 50 patients in the study and control groups completed the study protocol. Almost equal numbers of inpatients and outpatients were recruited for both the groups. The mean age was 29.6 years in study group and 31.2 years in the control group. All the cases were fresh, and the duration varied from 6 months to 15 months. Mean duration of the illness was 9.6 months for the study group and 8.7 months for the control group. Social variables like marital status, rural/ urban domicile and educational status were comparable between the groups. Almost two thirds of the patients had illness for less than 6 months when they were taken up for the study. In both the groups, there was almost similar representation for both the sexes. Mixed anxiety and depressive disorder was the most common psychiatric diagnosis in both the sexes, but obsessive compulsive disorder was overrepresented among females.

In the study group, at the beginning of the study 13 patients showed severe anxiety on Hamilton Anxiety Scale (HAS) [Table 1]. This number came down to 12 by the end of 4 weeks; and to 11, by the end of 8 weeks. But 28 patients had moderate anxiety in the beginning; this number came down significantly to 24 by the end of 4 weeks; and to 21, by the end of 8 weeks. Mild anxiety was noted in 9 patients initially, decreasing to 7 patients by 4 weeks and to 4 patients by the end of 8 weeks of therapy. Also 14 of the
patients showed no anxiety on HAS score by the end of 8 weeks of therapy. The mean HAS score in the beginning was 45 in the severe anxiety group, 27.5 in moderate anxiety group and 22.6 in mild anxiety group, which came down to 37, 26.3 and 19.6, respectively, by the end of 8 weeks of therapy [Table 2].

With Taylor's Manifest Anxiety Scale (TMAS), in the beginning of the study, 15 patients of the study group showed severe anxiety [Table 3]; this number came down to 13 by the end of 4 weeks; and to 11 patients, by the end of 8 weeks of therapy. Twenty-four patients had moderate anxiety initially; this number came down to 21 by the end of 4 weeks; and to 18, by the end of the study. Similarly there were 11 patients with mild anxiety initially; 8, by the end of 4 weeks; and 5 patients, by the end of 8 weeks. Also by the end of 8 weeks, 16 patients showed no anxiety on TMAS.

The mean TMAS score in the beginning was 44.2 in the severe anxiety group, 33.9 in the moderate anxiety group and 29.7 in the mild anxiety group, which came down to 39.7, 31.6 and 26.4 by eight weeks respectively. Analysis of reduction in mean TMAS score showed that there was no significant reduction in the mild anxiety group [Table 4], but the reduction was statistically significant in both moderate and severe anxiety groups.

DISCUSSION

 Various syndromal psychiatric disorders with prominent anxiety symptoms were taken up in this study for both study group and control group. The distributions of social variables and psychiatric diagnoses were comparable between groups.

 The diagnosis was made clinically using ICD-10 criteria. But for the objective assessment of the level of anxiety, two well-validated psychometric scales, namely, Hamilton Anxiety Scale (HAS) and Taylor’s Manifest Anxiety Scale (TMAS), were used. By combining these two scales, one could assess the maximum number of measurable symptoms of anxiety.

 In both the groups, the improvement over the treatment duration was noticed in cases with all the psychiatric diagnoses; however, the response was better for mixed anxiety and depressive disorder in the control group using anxiolytics than in the study group using biofeedback. This is probably because of the prominent depressive symptoms which have not been documented to be sensitive to biofeedback therapy. Similar findings have been noticed by Col. Saldanha et al.[5] but it was noticed that cases of generalized anxiety disorder (GAD) and obsessive compulsive disorder (OCD) in both the groups improved better than those of other diagnostic categories. This is in line with the findings by Rice et al. [9]

 In the study group, female patients showed better response by the end of 8 weeks of treatment, whereas the response was almost similar between the sexes in the control group. Female patients were more willing to use biofeedback therapy versus medication and were more regular in attending the sessions than the male patients. It has been shown in the past that patients with high belief in biofeedback therapy respond better to it.[10] Probably, similar factors played a key role in the efficacy of therapy in the study group.

 Improvement with biofeedback therapy was noticed even by the end of 4 weeks and continued uniformly till the end of 8 weeks of therapy. Using HAS, no significant difference was noticed in efficacy between biofeedback and pharmacotherapy in the mild and severe anxiety patients of the two groups, but biofeedback was less efficacious than pharmacotherapy for the moderate anxiety group. Also, the number of patients with no anxiety at the end of 8 weeks was higher in the control group. On TMAS score, the improvement was more pronounced in the control group, but patients with severe anxiety showed better response with biofeedback than with pharmacotherapy.

 To conclude, this study has shown that in the short term, EEG biofeedback therapy is almost as efficacious as pharmacological intervention in the management of anxiety symptoms of patients with psychiatric diagnoses. It was found to be relatively more useful in females and those with GAD and OCD.

 However, it will not be prudent to generalize the above findings due to certain limitations of the study. Due to certain limitations with regard to duration of hospitalization for serving soldiers, the study duration was planned for 8 weeks only. Continued benefit of the biofeedback therapy over a longer
duration and absence of recurrence of symptoms on cessation of therapy can only be assessed when the treatment is followed up for a longer duration.

Footnotes

Source of Support: Nil.

Conflict of Interest: None declared.

REFERENCES


Figures and Tables

Table 1

<table>
<thead>
<tr>
<th>Score</th>
<th>Initial phase</th>
<th>After 4 weeks</th>
<th>After 8 weeks</th>
</tr>
</thead>
<tbody>
<tr>
<td>No anxiety (&lt;18)</td>
<td>–</td>
<td>15.3 (7)</td>
<td>12.1 (14)</td>
</tr>
<tr>
<td>Mild anxiety (18-24)</td>
<td>22.6 (9)</td>
<td>20.3 (7)</td>
<td>19.6 (4)</td>
</tr>
<tr>
<td>Moderate anxiety (25-29)</td>
<td>27.5 (28)</td>
<td>28.2 (24)</td>
<td>26.3 (21)</td>
</tr>
<tr>
<td>Severe anxiety (30 and more)</td>
<td>45 (13)</td>
<td>43 (12)</td>
<td>37 (11)</td>
</tr>
</tbody>
</table>

Mean Hamilton Anxiety Scale scores in the study group

Table 2

www.ncbi.nlm.nih.gov/pmc/articles/PMC3237126/?report=printable
Efficacy of Alfa EEG wave biofeedback in the management of anxiety

Comparison of mean Hamilton Anxiety Scale scores (initial vs. after 8 weeks) in the study group (n=50)

<table>
<thead>
<tr>
<th>Score</th>
<th>Mean score (SD)</th>
<th>P</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial phase</td>
<td>After 8 weeks</td>
<td></td>
</tr>
<tr>
<td>No anxiety (&lt;18)</td>
<td>–</td>
<td>12.1 (2.1)</td>
<td>No sample initially</td>
</tr>
<tr>
<td>Mild anxiety (18-24)</td>
<td>22.6 (2.67)</td>
<td>19.6 (1.86)</td>
<td>0.069 t=2.02; SE=1.4876</td>
</tr>
<tr>
<td>Moderate anxiety (25-29)</td>
<td>27.5 (3.78)</td>
<td>26.3 (4.39)</td>
<td>0.310 t=1.03; SE=1.1694</td>
</tr>
<tr>
<td>Severe anxiety (30 and more)</td>
<td>45 (4.63)</td>
<td>37 (4.29)</td>
<td>0.000 t=4.36; SE=1.8348</td>
</tr>
</tbody>
</table>

SD= Standard deviation

Table 3

Mean Taylor's Manifest Anxiety Scale scores in the study group

<table>
<thead>
<tr>
<th>Score</th>
<th>Mean score (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial phase</td>
</tr>
<tr>
<td>No anxiety (25 and less)</td>
<td>–</td>
</tr>
<tr>
<td>Mild anxiety (26-30)</td>
<td>29.7 (11)</td>
</tr>
<tr>
<td>Moderate anxiety (31-35)</td>
<td>33.9 (24)</td>
</tr>
<tr>
<td>Severe anxiety (36 and above)</td>
<td>44.2 (15)</td>
</tr>
</tbody>
</table>

Table 4
<table>
<thead>
<tr>
<th>Score</th>
<th>Mean score (SD)</th>
<th>P</th>
<th>Significance</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Initial phase</td>
<td>After 8 weeks</td>
<td></td>
</tr>
<tr>
<td>No anxiety (&lt;18)</td>
<td>–</td>
<td>16.9 (1.4)</td>
<td>No sample initially</td>
</tr>
<tr>
<td>Mild anxiety (18-24)</td>
<td>29.7 (3.17)</td>
<td>26.4 (2.67)</td>
<td>0.265</td>
</tr>
<tr>
<td>Moderate anxiety (25-29)</td>
<td>33.9 (2.87)</td>
<td>31.6 (2.43)</td>
<td>0.009</td>
</tr>
<tr>
<td>Severe anxiety (30 and more)</td>
<td>44.2 (3.16)</td>
<td>39.7 (2.95)</td>
<td>0.001</td>
</tr>
</tbody>
</table>

Comparison of mean Taylor's Manifest Anxiety Scale scores (initial vs. after 8 weeks) in the study group.